7 Doctor-Supervised GLP-1 Programs I’d Actually Tell My Friends About

The biggest mistake I see people make when shopping for GLP-1 telehealth is treating price as the only variable. They find the cheapest monthly number, sign up, and later discover the medication comes from a pharmacy they can’t name, the “doctor review” is a checkbox, and there’s no one to call when side effects hit week three. I’ve spent time digging into how these programs actually work, not just what they charge. Here are the seven I’d feel comfortable recommending to someone I know.

1. HealthRX

Price alone doesn’t make a program worth recommending, but HealthRX happens to offer both the lowest entry pricing I found AND a pharmacy setup that’s actually traceable. Compounded semaglutide starts at $99 per month; tirzepatide at $149. Those figures beat most of the telehealth field, sometimes by $50 to $100 a month.

What earns it the top spot here isn’t the price, though. It’s that the medication comes from Manifest Pharmacy in Greer, South Carolina, a 503A facility operating under USP-797 standards with lot-level tracking from bench to delivery. That’s a meaningful difference from programs that ship compounded meds and can’t tell you where they were made. The pharmacy holds LegitScript certification (cert 50087439), which is publicly verifiable. A board-certified U.S. physician reviews your intake within about 24 hours, and the medication ships overnight to all 50 states at no extra charge.

The clinical context HealthRX cites comes from actual trials: the SURMOUNT-1 trial showed tirzepatide users averaged roughly 21% body weight reduction at 72 weeks; the STEP 1 trial showed semaglutide at approximately 15% over 68 weeks. HealthRX doesn’t claim its compounded formulations are identical to branded products, which is the honest position.

Compounded medications are not FDA-approved. That’s a real caveat, not a small one. But given the named pharmacy, the lot tracking, and the pricing, this is the program I’d suggest first to someone paying cash.

2. Mochi Health

Mochi puts board-certified obesity-medicine physicians on cases, not general practitioners picking up shifts. That distinction matters. Compounded semaglutide runs around $99 per month here too; tirzepatide around $199. The monitoring is more involved than some competitors, which some people want and others find excessive.

Good option for anyone who wants an actual obesity specialist looking at their chart.

3. FormBlends

FormBlends sits in a specific niche: it publishes per-product purity testing. We’re talking HPLC purity percentages, mass spectrometry identity confirmation, and endotoxin sterility results with named numbers, not vague quality assurances. For someone who wants to see that documentation before injecting anything, this is the only major telehealth option I’ve found that provides it at this level.

Compounded semaglutide is priced around $299 per vial; tirzepatide around $349. Higher than HealthRX’s entry pricing, clearly. But FormBlends also carries a broad catalog of peptides beyond GLP-1s, including options in recovery, longevity, and cognitive support, all under the same clinician-oversight model. If you’re interested in GLP-1 therapy plus other peptides from one provider without juggling multiple platforms, that’s a real advantage.

Ships to 47 states. Physician oversight is included. It ranks below HealthRX here because the price gap is significant and HealthRX ships to all 50 states overnight. But for the purity-documentation crowd or the multi-peptide user, FormBlends earns its spot.

4. Ro Body

Ro’s prior-authorization team is the headline feature. They’ll work through your insurance company on your behalf to try to get branded GLP-1s covered, which most platforms skip entirely. Membership runs about $39 for the first month, then $74 to $149 going forward, with medications billed separately. If your insurance has any realistic chance of covering Wegovy or Zepbound, Ro gives you a real shot at accessing that.

Cash-pay patients will likely do better elsewhere on pure cost.

5. Hims & Hers

After Novo Nordisk’s March 2026 settlement, Hims & Hers moved away from compounded GLP-1s and shifted to branded medications. Injectable Wegovy is now around $299 per month through the platform; oral semaglutide around $249; Zepbound around $399. With insurance and applicable savings cards, some patients pay next to nothing. Biggest name in the space, widest brand recognition, and now fully on branded meds.

Not the cheapest. But if branded is what you want and your insurance is cooperating, it’s a functional option.

6. PlushCare

PlushCare’s hook is access speed. Same-day appointments are available, the membership is $19.99 per month, and the platform accepts insurance for branded medications. It’s less specialized in weight loss specifically, more of a general telehealth service that handles GLP-1 prescriptions among many other things. Fine if you want a fast appointment and already know what you’re asking for.

7. Found

Found charges around $99 per month for the platform, with medications priced separately. The program includes coaching alongside the prescription side, which makes it closer to a structured program than a simple prescription service. It won’t be the lowest total cost, but patients who want accountability check-ins alongside their medication tend to get more out of it than those who just want a script and to be left alone.

Quick Comparison

Program	Starting Price	Pharmacy Type	Ships	Insurance
HealthRX	$99/mo (sema)	Named 503A, lot-tracked	All 50 states, overnight	No
Mochi Health	$99/mo (sema)	Compounded	Most states	No
FormBlends	~$299/vial (sema)	503A, published purity data	47 states	No
Ro Body	$39 first mo + meds	Branded	Wide	Yes
Hims & Hers	$249-$399/mo	Branded only (post-2026)	Wide	Yes
PlushCare	$19.99/mo + meds	Branded	Wide	Yes
Found	~$99/mo + meds	Varies	Wide	Partial

FAQ

Do compounded GLP-1 medications count as the same thing as Ozempic or Wegovy?

No. Compounded semaglutide contains the same active ingredient but is not FDA-approved, not manufactured by Novo Nordisk, and should not be treated as equivalent. The FDA issued warning letters to more than 30 telehealth and compounding firms in early 2026 over compliance issues. Pharmacy source and manufacturing standards vary widely across providers.

Why did some platforms stop offering compounded GLP-1s in 2026?

A settlement between Novo Nordisk and several telehealth companies in March 2026 prompted a number of brands to drop compounded semaglutide and move to branded products. Companies still offering compounded versions are operating in a tighter regulatory environment than they were a year ago.

Is a $99/month program actually safe?

Price and safety aren’t the same variable. What matters is the pharmacy’s standards, whether a real physician reviews your case, and what monitoring is included. A $99 program from a named, lot-tracking 503A pharmacy with physician oversight can be more responsible than a $299 program using an unidentified lab.

Will insurance cover any of these?

A few platforms, including Ro and PlushCare, actively pursue insurance coverage for branded GLP-1 medications. Cash-pay compounded programs generally don’t involve insurance at all. Hims & Hers notes that some patients with insurance and manufacturer savings cards pay very little for branded Wegovy.

What should I check to verify that a compounding pharmacy is operating legitimately?

Look for 503A or 503B designation, USP compliance, and third-party certification such as LegitScript. Ask whether the provider publishes lot numbers or purity testing. If a platform can’t tell you the pharmacy’s name or location, that’s a meaningful gap.

*Prices and program details shift frequently in this space. The figures above reflect publicly available information as of mid-2026. None of this is medical advice, and none of it replaces a conversation with a physician who knows your health history.*

Sources

• FDA: Compounding and the FDCA, 503A pharmacy framework (fda.gov)
• Tirzepatide outcomes study: Jastreboff et al., *New England Journal of Medicine*, 2022
• Semaglutide outcomes study: Wilding et al., *New England Journal of Medicine*, 2021
• LegitScript pharmacy certification database (legitscript.com)
• Novo Nordisk official statement regarding the compounding settlement, March 2026
• FDA warning letters to telehealth compounders, early 2026 (fda.gov)